These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

239 related articles for article (PubMed ID: 38918793)

  • 1. Mitochondrial GCN5L1 acts as a novel regulator for iron homeostasis to promote sorafenib sensitivity in hepatocellular carcinoma.
    Hu X; Zhang P; Li S; Zhang J; Wang D; Wang Z; Zhu L; Wang L
    J Transl Med; 2024 Jun; 22(1):593. PubMed ID: 38918793
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sorafenib induces mitochondrial dysfunction and exhibits synergistic effect with cysteine depletion by promoting HCC cells ferroptosis.
    Li Y; Xia J; Shao F; Zhou Y; Yu J; Wu H; Du J; Ren X
    Biochem Biophys Res Commun; 2021 Jan; 534():877-884. PubMed ID: 33162029
    [TBL] [Abstract][Full Text] [Related]  

  • 3. PLAG1 interacts with GPX4 to conquer vulnerability to sorafenib induced ferroptosis through a PVT1/miR-195-5p axis-dependent manner in hepatocellular carcinoma.
    Li J; Li Y; Wang D; Liao R; Wu Z
    J Exp Clin Cancer Res; 2024 May; 43(1):143. PubMed ID: 38745179
    [TBL] [Abstract][Full Text] [Related]  

  • 4. MCM4 potentiates evasion of hepatocellular carcinoma from sorafenib-induced ferroptosis through Nrf2 signaling pathway.
    Liu X; Zhang F; Fan Y; Qiu C; Wang K
    Int Immunopharmacol; 2024 Dec; 142(Pt A):113107. PubMed ID: 39276458
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Genome-scale CRISPRa screening identifies MTX1 as a contributor for sorafenib resistance in hepatocellular carcinoma by augmenting autophagy.
    Li L; Yu S; Hu Q; Hai Y; Li Y
    Int J Biol Sci; 2021; 17(12):3133-3144. PubMed ID: 34421355
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Glycyrrhizic acid attenuates sorafenib resistance by inducing ferroptosis via targeting mTOR signaling in hepatocellular carcinoma.
    Hu Y; Luo Z; Cai S; Xie Q; Zheng S
    Scand J Gastroenterol; 2024 Jun; 59(6):730-736. PubMed ID: 38426342
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Epigenetic regulation of ferroptosis via ETS1/miR-23a-3p/ACSL4 axis mediates sorafenib resistance in human hepatocellular carcinoma.
    Lu Y; Chan YT; Tan HY; Zhang C; Guo W; Xu Y; Sharma R; Chen ZS; Zheng YC; Wang N; Feng Y
    J Exp Clin Cancer Res; 2022 Jan; 41(1):3. PubMed ID: 34980204
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Protein phosphatase 2A-B55β mediated mitochondrial p-GPX4 dephosphorylation promoted sorafenib-induced ferroptosis in hepatocellular carcinoma via regulating p53 retrograde signaling.
    Qian B; Che L; Du ZB; Guo NJ; Wu XM; Yang L; Zheng ZX; Gao YL; Wang MZ; Chen XX; Xu L; Zhou ZJ; Lin YC; Lin ZN
    Theranostics; 2023; 13(12):4288-4302. PubMed ID: 37554285
    [No Abstract]   [Full Text] [Related]  

  • 9. Exosome-derived circUPF2 enhances resistance to targeted therapy by redeploying ferroptosis sensitivity in hepatocellular carcinoma.
    Dong FL; Xu ZZ; Wang YQ; Li T; Wang X; Li J
    J Nanobiotechnology; 2024 May; 22(1):298. PubMed ID: 38811968
    [TBL] [Abstract][Full Text] [Related]  

  • 10. EZH2 suppresses ferroptosis in hepatocellular carcinoma and reduces sorafenib sensitivity through epigenetic regulation of TFR2.
    Lai Y; Han X; Xie B; Xu Y; Yang Z; Wang D; Li W; Xie Y; Song W; Zhang X; Xia JQ; Zhang P
    Cancer Sci; 2024 Jul; 115(7):2220-2234. PubMed ID: 38623968
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Loss of GCN5L1 exacerbates damage in alcoholic liver disease through ferroptosis activation.
    Yang C; Yang Y; Hu X; Tang Q; Zhang J; Zhang P; Lu X; Xu J; Li S; Dong Z; Zhu L; Wang L
    Liver Int; 2024 Aug; 44(8):1924-1936. PubMed ID: 38597373
    [TBL] [Abstract][Full Text] [Related]  

  • 12. DDX39B protects against sorafenib-induced ferroptosis by facilitating the splicing and cytoplasmic export of GPX4 pre-mRNA in hepatocellular carcinoma.
    Li Q; Yuan H; Zhao G; Ou D; Zhang J; Li L; Li S; Feng T; Gu R; Kou Q; Wang Q; Li S; Wang G; Zhao M; Yu H; Qu J; Lin P; Li K
    Biochem Pharmacol; 2024 Jul; 225():116251. PubMed ID: 38701867
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CCT3/ACTN4/TFRC axis protects hepatocellular carcinoma cells from ferroptosis by inhibiting iron endocytosis.
    Zhu H; Liu Q; Meng Q; Zhang L; Ju S; Lang J; Zhu D; Chen Y; Aishan N; Ouyang X; Zhang S; Jin L; Xiao L; Wang L; Li L; Ji F
    J Exp Clin Cancer Res; 2024 Aug; 43(1):245. PubMed ID: 39210442
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phosphorylated FOXQ1, a novel substrate of JNK1, inhibits sorafenib-induced ferroptosis by activating ETHE1 in hepatocellular carcinoma.
    Liu Y; Shao K; Yang W; Shen Q; Lu M; Shao Z; Chu S; Wang Y; Wang X; Chen X; Bai J; Wu X
    Cell Death Dis; 2024 Jun; 15(6):395. PubMed ID: 38839744
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Benja-ummarit induces ferroptosis with cell ballooning feature through ROS and iron-dependent pathway in hepatocellular carcinoma.
    Sandech N; Yang MC; Juntranggoor P; Rukthong P; Gorelkin P; Savin N; Timoshenko R; Vaneev A; Erofeev A; Wichaiyo S; Pradidarcheep W; Maiuthed A
    J Ethnopharmacol; 2024 Dec; 335():118672. PubMed ID: 39127118
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tmem39b promotes tumor progression and sorafenib resistance by inhibiting ferroptosis in hepatocellular carcinoma.
    Zhuang M; Zhang X; Li LU; Wen L; Qin J
    Oncol Res; 2024; 32(8):1347-1357. PubMed ID: 39055886
    [TBL] [Abstract][Full Text] [Related]  

  • 17. SPARC regulates ferroptosis induced by sorafenib in human hepatocellular carcinoma.
    Hua HW; Jiang HS; Jia L; Jia YP; Yao YL; Chen YW; Jiang F; Lu DQ; Zhou Q; Jiang MW; Ding G
    Cancer Biomark; 2021; 32(4):425-433. PubMed ID: 33843664
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Time Course of Changes in Sorafenib-Treated Hepatocellular Carcinoma Cells Suggests Involvement of Phospho-Regulated Signaling in Ferroptosis Induction.
    Werth EG; Rajbhandari P; Stockwell BR; Brown LM
    Proteomics; 2020 May; 20(10):e2000006. PubMed ID: 32336023
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dihydroartemisinin induces ferroptosis of hepatocellular carcinoma via inhibiting ATF4-xCT pathway.
    Ji J; Cheng Z; Zhang J; Wu J; Xu X; Guo C; Feng J
    J Cell Mol Med; 2024 Apr; 28(8):e18335. PubMed ID: 38652216
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Artesunate synergizes with sorafenib to induce ferroptosis in hepatocellular carcinoma.
    Li ZJ; Dai HQ; Huang XW; Feng J; Deng JH; Wang ZX; Yang XM; Liu YJ; Wu Y; Chen PH; Shi H; Wang JG; Zhou J; Lu GD
    Acta Pharmacol Sin; 2021 Feb; 42(2):301-310. PubMed ID: 32699265
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.